NEUROGENE

neurogene-logo

Neurogene is a developer of generic medicines intended to improve patient outcomes for neurological disorders.The company's offerings include advancing genetic medicines for many neurological disorders where no effective treatment options exist, providing patients and families affected by rare neurological disorders with gene therapy that improves quality of life.

#SimilarOrganizations #People #Financial #Website #More

NEUROGENE

Social Links:

Industry:
Biotechnology

Founded:
2018-01-01

Address:
New York, New York, United States

Country:
United States

Website Url:
http://www.neurogene.com

Total Employee:
11+

Status:
Active

Total Funding:
68.5 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network


Similar Organizations

autobahn-therapeutics-logo

Autobahn Therapeutics

Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.

rainier-therapeutics-logo

Rainier Therapeutics

Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.

tiburio-therapeutics-logo

Tiburio Therapeutics

Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.


Current Advisors List

srdjan-stankovic_image

Srdjan Stankovic Member Board Of Directors @ Neurogene
Board_member
2019-02-01

Current Employees Featured

rachel-mcminn_image

Rachel McMinn
Rachel McMinn President & CEO @ Neurogene
President & CEO
2018-01-01

steve-pincus_image

Steve Pincus
Steve Pincus Executive Director Analytical Development @ Neurogene
Executive Director Analytical Development
2021-02-01

Founder


rachel-mcminn_image

Rachel McMinn

Investors List

ecor1-capital_image

EcoR1 Capital

EcoR1 Capital investment in Series A - Neurogene

samsara-biocapital_image

Samsara BioCapital

Samsara BioCapital investment in Series A - Neurogene

redmile-group_image

Redmile Group

Redmile Group investment in Series A - Neurogene

cormorant-asset-management_image

Cormorant Asset Management

Cormorant Asset Management investment in Series A - Neurogene

Official Site Inspections

http://www.neurogene.com Semrush global rank: 3.58 M Semrush visits lastest month: 4.02 K

  • Host name: 141.193.213.10
  • IP address: 141.193.213.10
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Neurogene"

Neurogene โ€“ Global Initiative in Neuropsychiatric Ethics

NeuroGenE is the Global Initiative in Neuropsychiatric Ethics based at the University of Oxford. We conduct global multidisciplinary research and capacity-building on the ethics of diagnosis, โ€ฆSee details»

About โ€“ Neurogene

NeuroGenE is a global research and capacity-building initiative exploring the multi-layered ethical challenges around psychiatry and neurodevelopmental diagnosis, prevention and intervention.See details»

Neurogene | Developing life-changing Genetic Medicines

Neurogene is focused on developing life-changing genetic medicines for patients & families affected by rare, devastating neurological diseases.See details»

Research โ€“ Neurogene

The NeuroGenE research programme examines the ethical challenges to the scientific research, and clinical and public policy application, of psychiatric genetics and genomics research with โ€ฆSee details»

Neurogene | About Us & the Future of Genetics in Medicine

Nov 13, 2018ย ยท At Neurogene, our focus is to develop life-changing genetic medicines for patients and their families affected by rare, devastating neurological diseases. Push the boundaries of โ€ฆSee details»

Neurogene | Our focus on Breakthroughs in Genetic โ€ฆ

Neurogene is focused on developing life-changing genetic medicines for patients and their families affected by rare, devastating neurological diseases. To accomplish this, we collaborate with many researchers, the patient โ€ฆSee details»

Neurogene - The Org

Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring to โ€ฆSee details»

Neurogene Inc. | Neurogene Reports Positive Interim Efficacy Data โ€ฆ

Nov 11, 2024ย ยท Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will โ€ฆSee details»

Ilina Singh's lab | University of Oxford (OX) - ResearchGate

NeuroGenE is the Global Initiative in Neuropsychiatric GenEthics based at the University of Oxford. We conduct global multidisciplinary research, training, and capacity-building on the โ€ฆSee details»

Neurogene - Crunchbase Company Profile & Funding

Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders. View contacts for Neurogene to access new leads and connect with โ€ฆSee details»

People โ€“ Neurogene

As core researchers of NeuroGenE, the Oxford team is comprised of interdisciplinary academics with particular research expertise in global mental health; neuroethics; disability rights and mental health advocacy; and โ€ฆSee details»

Neurogene Inc. | Investor Relations

Nov 18, 2024ย ยท The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing โ€ฆSee details»

Neurogene Inc. | Neurogene Provides Update on NGN-401 Gene โ€ฆ

Nov 18, 2024ย ยท NEW YORK --(BUSINESS WIRE)--Nov. 18, 2024-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients โ€ฆSee details»

Rachel McMinn - CEO at Neurogene - The Org

Dr. McMinn founded Neurogene in January 2018 with the mission of providing genetic medicines to improve the lives of neurologically-impaired and developmentally-delayed children and their โ€ฆSee details»

Neurogene's CEO and Executive Team - Team members and org โ€ฆ

Neurogene's CEO and Executive Team includes Ricardo Jimenez and 7 others.See details»

Who Funds Us โ€“ Neurogene

NeuroGenE receives core funding from the Stanley Centre for Psychiatric Research at the Broad Institute of Harvard and MIT. To date, we have received further support from the Wellcome โ€ฆSee details»

Additional Resources - Neurogene

Global Genes is an organization that helps to build awareness, educate the global community, and provide critical connections and resources that equip advocates to become activists for โ€ฆSee details»

Neurogene Releases Update on NGN-401 Clinical Trial High Dose

Nov 18, 2024ย ยท You can read more details in Neurogeneโ€™s release in the link below. The key information that Neurogene shared is that one patient, the child who was the third to receive โ€ฆSee details»

Funders & Partners โ€“ Neurogene

We rely on our funders and partners to ensure we achieve our main goal of establishing a world-class model for sustainable and integrated research, capacity-building, and training initiatives โ€ฆSee details»

Trofinetide benefits the ability to communicate in Rett syndrome: a ...

Nov 18, 2024ย ยท AK Percy is coeditor of Translational Science of Rare Diseases, received research funding from the National Institutes of Health, and is a consultant for Acadia Pharmaceuticals โ€ฆSee details»

linkstock.net © 2022. All rights reserved